Shanghai Hengrui Pharmaceutical Co., Ltd.

Quick facts

Marketed products

• Dexmedetomidine Hydrochloride Nasal Spray

Phase 3 pipeline

• Adebrelimab injection · Oncology
  Adebrelimab is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 receptors on immune cells.
• Paclitaxel, Docetaxel, Irinotecan · Oncology
  Paclitaxel, Docetaxel, and Irinotecan are microtubule inhibitors that work by stabilizing microtubules, thereby inhibiting cell division.
• SHR-8068 injection · Oncology
  SHR-8068 is a humanized monoclonal antibody that targets and inhibits the PD-L1 checkpoint protein to enhance anti-tumor immune responses.
• SHR-A1904 · Oncology
  SHR-A1904 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.
• SHR-A1912 · Oncology
  SHR-A1912 is a small molecule targeting the PD-1 receptor.
• SHR-A2102 for Injection · Oncology
  SHR-A2102 for Injection is a monoclonal antibody targeting PD-1.
• SHR6508 plus oral placebo tablets · unknown
  SHR6508 is a small molecule drug that targets the molecular target.
• Sodium Chloride Physiological Solution · Supportive Care / Fluid and Electrolyte Management
  Sodium chloride physiological solution restores and maintains electrolyte balance and fluid homeostasis by providing isotonic saline replacement.

Phase 2 pipeline

• Alomnertinib Mesilate · Oncology
  Alomnertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.
• Ametinib Mesylate Tablets
• Furmonertini Mesilate
• ropivacaine HCl.
• SHR-1707
• SHR-4602
• SHR-A2102
• SHR1819
• SHR6508

Phase 1 pipeline

• HR19024
• HRS-4642;nab-paclitaxel; gemcitabine
• HRS-6257
• HRS2398
• HRS2398 Tablets
• HRS8807
• HRS8807、SHR6390
• SHR-1501, Adebrelimab
• SHR-2005
• SHR-3836 administered as multiple doses.
• SHR-7367
• SHR-9839
• SHR-9839 ； Almonertinib
• SHR-9839 ； pemetrexed ；carboplatin
• SHR-9839 ； SHR-A1921
• SHR-9839 ；SHR-A2009
• SHR-A1904; Adebrelimab
• SHR-A1904; CAPOX; Adebrelimab
• SHR-A1912; R-Chemo
• SHR-A2102；Adebrelimab；Cisplatin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Hengrui Pharmaceutical Co., Ltd. portfolio CI brief
• Shanghai Hengrui Pharmaceutical Co., Ltd. pipeline updates RSS